Tech Company Financing Transactions
Resalis Therapeutics Funding Round
Resalis Therapeutics secured a $10.6 million Seed investment round on 2/22/2023. Investors included Claris Ventures, Club degli Investitori and Italian Angels for Growth.
Transaction Overview
Company Name
Announced On
2/22/2023
Transaction Type
Venture Equity
Amount
$10,601,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to support the finalization of IND-enabling studies for its lead program, RES-010.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Via Nizza 52
Turin, 10126
IT
Turin, 10126
IT
Phone
Undisclosed
Website
Email Address
Overview
Resalis Therapeutics' transformative metabolic disease approach targets a master regulator of key pathways underlying obesity and fatty liver disease. The company is applying its unique understanding of the non-coding RNA drug modality and lipid metabolism to develop its lead program, RES-010, into a safe and convenient treatment providing disease-modifying therapeutic impact including durable weight loss and reduction of hepatic steatosis.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Alessandro Toniolo
Browse more venture capital transactions:
Prev: 2/22/2023: sovity venture capital transaction
Next: 2/22/2023: DrDoctor venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC transactions on this site are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs